ClinicalTrials.gg
CompletedNCT03228680Updated Aug 24, 2023Results posted

Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women

A Phase 3 interventional study of Follitropin delta and Follitropin beta in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 17 sites in Japan. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-08-24.

Sponsored by Ferring Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
373
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.

Enrollment
4th of 13
373 · median 220
Started
2017
the only one that year
Phase 3
6 of 13
none open now
Registered
5th of 13
by date
Lead sponsor
10 of 13
Ferring Pharmaceuticals

Among the 13 studies testing follitropin delta in Infertility, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 5th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About follitropin delta

follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing follitropin delta in Infertility, or all of them as a file.
02

Study summary

To demonstrate non-inferiority of FE 999049 compared to FOLLISTIM with respect to number of oocytes retrieved in Japanese IVF/ICSI patients undergoing controlled ovarian stimulation.

03

Conditions studied

  • Infertility

Browse trials for

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documents signed prior to any trial-related procedures.
  • In good physical and mental health.
  • Japanese females between the ages of 20 and 40 years.
  • Infertile women diagnosed with tubal infertility, unexplained infertility, endometriosis stage I/II (defined by the revised American Society for Reproductive Medicine (ASRM) classification) or with partners diagnosed with male factor infertility, eligible for in vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI) treatment using ejaculated sperm from male partner.
  • Infertility for at least 1 year before randomization (not applicable in case of tubal or severe male factor infertility).
  • The trial cycle will be the participant's first controlled ovarian stimulation cycle for IVF/ICSI.
  • Hysterosalpingography, hysteroscopy, saline infusion sonography or transvaginal ultrasound documenting a uterus consistent with expected normal function (e.g. no evidence of clinically interfering uterine fibroids defined as submucous or intramural fibroids larger than 3 cm in diameter, no polyps and no congenital structural abnormalities which are associated with a reduced chance of pregnancy) within 1 year prior to screening. This also includes women who have been diagnosed with any of the above medical conditions but have had them surgically corrected within 1 year prior to screening.
  • Transvaginal ultrasound documenting presence and adequate visualization of both ovaries, without evidence of significant abnormality (e.g. no endometrioma greater than 3 cm or enlarged ovaries which would contraindicate the use of gonadotropins) and fallopian tubes and surrounding tissue without evidence of significant abnormality (e.g. no hydrosalpinx) within 1 year prior to screening. Both ovaries must be accessible for oocyte retrieval.
  • Early follicular phase (cycle day 2-4) serum levels of follicle stimulating hormone (FSH) between 1 and 15 IU/L (results obtained within 3 months prior to screening).
  • (BMI) between 17.5 and 32.0 kg/m\^2 (both inclusive) at screening.

Exclusion criteria

Exclusion Criteria:

  • Known endometriosis stage III-IV (defined by the revised ASRM classification).
  • One or more follicles >10 mm (including cysts) observed on the transvaginal ultrasound prior to start of stimulation on stimulation day 1 (puncture of cysts prior randomization is allowed).
  • Known history of recurrent miscarriage (defined as three consecutive losses after ultrasound confirmation of pregnancy (excl. ectopic pregnancy) and before week 24 of pregnancy).
  • Known abnormal karyotype of participant or of her partner. In case the sperm production is severely impaired (concentration \<1 million/mL), normal karyotype, including no Y chromosome microdeletion, must be documented.
  • Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events.
  • Any known systemic disease (e.g. insulin-dependent diabetes).
  • Any known endocrine or metabolic abnormalities (pituitary, adrenal, pancreas, liver or kidney) which can compromise participation in the trial with the exception of controlled thyroid function disease.
  • Known tumours of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus which would contraindicate the use of gonadotropins.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
373 participants (actual)

Study arms

  • Experimental
    Follitropin delta

    FE 999049 was administered as single daily subcutaneous injections in the abdomen. Participants randomized to FE 999049 had their individual dose determined on the basis of their anti-Müllerian hormone (AMH) level at screening and their body weight at randomization. The daily FE 999049 dose was fixed throughout the stimulation period. The minimum allowed daily FE 999049 dose was 6 μg and maximum allowed daily dose was 12 μg. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.

    Drug: Follitropin delta

  • Active comparator
    Follitropin beta

    FOLLISTIM was administered as single daily subcutaneous injections in the abdomen. The starting dose of FOLLISTIM was 150 IU and fixed for the first five stimulation days, after which it could be adjusted by 75 IU based on the individual response. The maximum allowed daily dose was 375 IU. Dosing continued until the criterion for triggering of final follicular maturation was met. Participants could be treated for a maximum of 20 days.

    Drug: Follitropin beta

Interventions

  • Single daily subcutaneous administration through pre-filled injection pen

    Also known as: FE 999049, REKOVELLE

  • Single daily subcutaneous injection in the abdomen

    Also known as: FOLLISTIM

06

What researchers measure

Primary outcomes

  1. Number of Oocytes Retrieved

    The number of oocytes retrieved was recorded at the oocyte retrieval visit.

    Time frame: 36h (± 2h) after triggering of final follicular maturation (On day of oocyte retrieval)

Secondary outcomes

  1. Clinical Pregnancy Rate

    Clinical pregnancy was defined as at least one gestational sac 5-6 weeks after transfer.

    Time frame: 5-6 weeks after transfer (up to approximately 3 months after start of stimulation)

  2. Positive Beta Unit of Human Chorionic Gonadotropin (Beta-hCG) Rate

    Defined as positive serum beta-hCG test 13-15 days after transfer.

    Time frame: 13-15 days after transfer (up to approximately 1.5 months after start of stimulation)

  3. Vital Pregnancy Rate

    Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer.

    Time frame: 5-6 weeks after transfer (up to approximately 3 months after start of stimulation)

  4. Implantation Rate

    Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by the number of blastocysts transferred.

    Time frame: 5-6 weeks after transfer (up to approximately 3 months after start of stimulation)

  5. Proportion of Participants With Cycle Cancellation Due to Poor or Excessive Ovarian Response

    Time frame: End-of-stimulation (up to 20 stimulation days)

  6. Proportion of Participants With Blastocyst Transfer Cancellation Due to Excessive Ovarian Response / OHSS Risk

    Time frame: End-of-stimulation (up to 20 stimulation days)

  7. Proportion of Participants With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved

    Defined as proportion of participants grouped according to the number of oocytes retrieved. The proportion of participants with \<4 oocytes (low response), 4-7 oocytes (moderate response), 8-14 oocytes (targeted response), 15-19 oocytes (hyperresponse) and ≥20 oocytes (severe hyperresponse) are presented.

    Time frame: On the day of oocyte retrieval (up to 22 days after start of stimulation)

  8. Proportion of Participants With Extreme Ovarian Responses (Defined as <4, ≥15 or ≥20 Oocytes Retrieved) in Risk Population

    Time frame: On the day of oocyte retrieval (up to 22 days after start of stimulation)

  9. Proportion of Participants With Preventive Interventions for Early Ovarian Hyperstimulation Syndrome (OHSS)

    Time frame: ≤9 days after triggering of final follicular maturation

  10. Proportions of Participants With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS

    Defined as proportion of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.

    Time frame: Up to 9 days after triggering of final follicular maturation

  11. Proportions of Participants With Late OHSS (Including OHSS of Moderate/Severe Grade)

    Defined as proportions of participants with late OHSS (including OHSS of moderate/severe grade). Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation. The proportion of participants with late OHSS, and late OHSS of moderate or severe grade are presented. All OHSS cases were graded as mild, moderate, or severe.

    Time frame: >9 days after triggering of final follicular maturation

  12. Number of Follicles on Stimulation Day 6

    Defined as the number of follicles observed in both ovaries at the last transvaginal ultrasound (TVUS) in the stimulation phase (on stimulation Day 6).

    Time frame: At Day 6 of stimulation

  13. Number of Follicles at End-of-stimulation

    Defined as the number of follicles observed in both ovaries at the last TVUS in the stimulation phase (end-of-stimulation).

    Time frame: End-of-stimulation (up to 20 stimulation days)

  14. Size of Follicles on Stimulation Day 6

    Defined as size characteristics of follicles on stimulation Day 6. Average size of 3 largest follicles has been presented in this endpoint.

    Time frame: At Day 6 of stimulation

  15. Size of Follicles at End-of-Stimulation

    Defined as size characteristics of follicles at end-of-stimulation. Average size of 3 largest follicles has been presented in this endpoint.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  16. Fertilization Rate

    The fertilization rate was defined as the number of oocytes with 2 pronuclei divided by the number of oocytes retrieved.

    Time frame: Day 1 after oocyte retrieval (up to approximately 22 days after start of stimulation)

  17. Number and Quality of Embryos

    Number of embryos (total and good-quality) on Day 3 are presented. A good-quality embryo was defined as an embryo with ≥6 blastomeres and fragmentation ≤20% on Day 3.

    Time frame: Day 3 after oocyte retrieval (up to approximately 24 days after start of stimulation)

  18. Number and Quality of Blastocysts

    Number of embryos (total and good-quality) on Day 5 are presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.

    Time frame: Day 5 after oocyte retrieval (up to approximately 26 days after start of stimulation)

  19. Circulating Levels of Endocrine Parameters (Follicle-stimulating Hormone [FSH], Luteinising Hormone [LH]) on Stimulation Day 6

    The median and inter-quartile range (IQR) of FSH and LH levels on stimulation Day 6 are presented.

    Time frame: At Day 6 of stimulation

  20. Circulating Levels of Endocrine Parameters (Follicle-stimulating Hormone [FSH], Luteinising Hormone [LH]) at End-of-stimulation

    The median and IQR of FSH and LH levels at end-of-stimulation are presented.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  21. Circulating Levels of Endocrine Parameter (Estradiol) on Stimulation Day 6

    The median and IQR of estradiol levels on stimulation Day 6 are presented.

    Time frame: At Day 6 of stimulation

  22. Circulating Levels of Endocrine Parameter (Estradiol) at End-of-stimulation

    The median and IQR of estradiol levels at end-of-stimulation are presented.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  23. Circulating Levels of Endocrine Parameter (Progesterone) on Stimulation Day 6

    The median and IQR of progesterone levels on stimulation Day 6 are presented.

    Time frame: At Day 6 of stimulation

  24. Circulating Levels of Endocrine Parameter (Progesterone) at End-of-stimulation

    The median and IQR of progesterone levels at end-of-stimulation are presented.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  25. Circulating Levels of Endocrine Parameters (Inhibin A) on Stimulation Day 6

    The median and IQR of Inhibin A levels on stimulation Day 6 are presented.

    Time frame: At Day 6 of stimulation

  26. Circulating Levels of Endocrine Parameters (Inhibin A) at End-of-stimulation

    The median and IQR of Inhibin A levels at end-of-stimulation are presented.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  27. Circulating Levels of Endocrine Parameters (Inhibin B) on Stimulation Day 6

    The median and IQR of inhibin B levels on stimulation Day 6 are presented.

    Time frame: At Day 6 of stimulation

  28. Circulating Levels of Endocrine Parameters (Inhibin B) at End-of-stimulation

    The median and IQR of inhibin B levels at end-of-stimulation are presented.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  29. Number of Stimulation Days

    Time frame: End-of-stimulation (up to 20 stimulation days)

  30. Total Gonadotropin Dose of FE 999049

    Time frame: End-of-stimulation (up to 20 stimulation days)

  31. Total Gonadotropin Dose of FOLLISTIM

    Time frame: End-of-stimulation (up to 20 stimulation days)

  32. Number of Participants With Adverse Events (AEs) Stratified by Intensity

    The frequency of participants with total AEs and AEs by categories of intensity (mild, moderate, severe) are presented. An AE was any untoward medical occurrence in a participants participating in clinical trial. The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activity); moderate = event sufficient to affect usual activity (disturbing); or severe = inability to work or perform usual activities (unacceptable).

    Time frame: From signed informed consent up to 5-6 weeks after transfer

  33. Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-stimulation

    Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) were reported. The clinical chemistry parameters included: alanine transaminase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  34. Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-stimulation

    Defined as number of participants with at least one markedly abnormal changes in hematology parameters (as assessed by investigator) were reported. Hematology parameters included: red blood cells, white blood cells, red blood cells morphology, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  35. Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-trial

    Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) were reported. The clinical chemistry parameters included: alanine transaminase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.

    Time frame: Up to 5-6 weeks after transfer

  36. Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-trial

    Defined as number of participants with at least one markedly abnormal changes in hematology parameters (as assessed by investigator) were reported. Hematology parameters included: red blood cells, white blood cells, red blood cells morphology, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.

    Time frame: Up to 5-6 weeks after transfer

  37. Frequency and Intensity of Injection Site Reactions

    The presence of of injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after the injection are presented. The injection site reactions were assessed as none, mild, moderate and severe. The number of injection site reactions (mild, moderate or severe) based on all assessments performed is presented.

    Time frame: End-of-stimulation (up to 20 stimulation days)

  38. Technical Malfunctions of the Administration Pens

    Time frame: End-of-stimulation (up to 20 stimulation days)

07

Results

Posted Mar 24, 2021

Participant flow

A total of 17 investigational sites in Japan randomized participants to the trial between 29 July 2017 to 08 July 2019.

Participant flow — Overall Study
MilestoneFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Started170178
Completed147143
Not completed2335
Withdrew: Adverse event1318
Withdrew: Randomization failure01
Withdrew: Withdrawal by subject10
Withdrew: Other916

Outcome measures

PrimaryNumber of Oocytes Retrieved

The number of oocytes retrieved was recorded at the oocyte retrieval visit.

Time frame:
36h (± 2h) after triggering of final follicular maturation (On day of oocyte retrieval)
Reported as:
Mean · Oocytes retrieved
Number of Oocytes Retrieved
Oocytes retrievedFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Number of Oocytes Retrieved9.3 ± 5.410.5 ± 6.1
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Mean difference (final values): -1.2 · 95% CI -2.3 to -0.1If the lower bound of 95% CI was well above pre-specified NI limit of -3.0 oocytes, then NI of FE 999049 to FOLLISTIM with respect to number of oocytes retrieved in women undergoing controlled ovarian stimulation would be demonstrated
SecondaryClinical Pregnancy Rate

Clinical pregnancy was defined as at least one gestational sac 5-6 weeks after transfer.

Time frame:
5-6 weeks after transfer (up to approximately 3 months after start of stimulation)
Reported as:
Number · percentage of participants
Clinical Pregnancy Rate
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Clinical Pregnancy Rate25.323.7
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Risk difference (rd): 1.6 · 95% CI -7.5 to 10.6The difference (FE 999049-FOLLISTIM) in rates was estimated and a two-sided 95% Cl was constructed using the Mantel-Haenszel method to combine results across AMH strata.
SecondaryPositive Beta Unit of Human Chorionic Gonadotropin (Beta-hCG) Rate

Defined as positive serum beta-hCG test 13-15 days after transfer.

Time frame:
13-15 days after transfer (up to approximately 1.5 months after start of stimulation)
Reported as:
Number · percentage of participants
Positive Beta Unit of Human Chorionic Gonadotropin (Beta-hCG) Rate
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Positive Beta Unit of Human Chorionic Gonadotropin (Beta-hCG) Rate29.429.4
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Risk difference (rd): 0.0 · 95% CI -9.5 to 9.6The difference (FE 999049-FOLLISTIM) in rates was estimated and a two-sided 95% Cl was constructed using the Mantel-Haenszel method to combine results across AMH strata.
SecondaryVital Pregnancy Rate

Vital pregnancy was defined as at least one intrauterine gestational sac with fetal heart beat 5-6 weeks after transfer.

Time frame:
5-6 weeks after transfer (up to approximately 3 months after start of stimulation)
Reported as:
Number · percentage of participants
Vital Pregnancy Rate
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Vital Pregnancy Rate23.521.5
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Risk difference (rd): 2.0 · 95% CI -6.7 to 10.8The difference (FE 999049-FOLLISTIM) in rates was estimated and a two-sided 95% Cl was constructed using the Mantel-Haenszel method to combine results across AMH strata.
SecondaryImplantation Rate

Implantation rate was defined as the number of gestational sacs 5-6 weeks after transfer divided by the number of blastocysts transferred.

Time frame:
5-6 weeks after transfer (up to approximately 3 months after start of stimulation)
Reported as:
Number · % of sacs/blastocysts transferred
Implantation Rate
% of sacs/blastocysts transferredFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Implantation Rate31.929.8
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Risk difference (rd): 1.9 · 95% CI -8.9 to 12.8The difference (FE 999049-FOLLISTIM) in rates was estimated and a two-sided 95% Cl was constructed using the Mantel-Haenszel method to combine results across AMH strata.
SecondaryProportion of Participants With Cycle Cancellation Due to Poor or Excessive Ovarian Response
Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · percentage of participants
Proportion of Participants With Cycle Cancellation Due to Poor or Excessive Ovarian Response
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Cycle cancelled due to poor ovarian response1.20.6
Cycle cancelled due to excessive ovarian response01.1
SecondaryProportion of Participants With Blastocyst Transfer Cancellation Due to Excessive Ovarian Response / OHSS Risk
Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · percentage of participants
Proportion of Participants With Blastocyst Transfer Cancellation Due to Excessive Ovarian Response / OHSS Risk
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Proportion of Participants With Blastocyst Transfer Cancellation Due to Excessive Ovarian Response / OHSS Risk7.611.3
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.244 (P-value was based on likelihood ratio chi-square test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
SecondaryProportion of Participants With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved

Defined as proportion of participants grouped according to the number of oocytes retrieved. The proportion of participants with \<4 oocytes (low response), 4-7 oocytes (moderate response), 8-14 oocytes (targeted response), 15-19 oocytes (hyperresponse) and ≥20 oocytes (severe hyperresponse) are presented.

Time frame:
On the day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Number · percentage of participants
Proportion of Participants With <4, 4-7, 8-14, 15-19 and ≥20 Oocytes Retrieved
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Low response (<4 oocytes)8.35.2
Moderate response (4-7 oocytes)36.126.6
Targeted response (8-14 oocytes)40.842.8
Hyperresponse (15-19 oocytes)10.114.5
Severe hyperresponse (≥ 20 oocytes)4.711.0
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.254 (P-value was based on likelihood ratio chi-square test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.041 (P-value was based on likelihood ratio test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.705 (P-value was based on likelihood ratio test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.183 (P-value was based on likelihood ratio test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.030 (P-value was based on likelihood ratio chi-square test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
SecondaryProportion of Participants With Extreme Ovarian Responses (Defined as <4, ≥15 or ≥20 Oocytes Retrieved) in Risk Population
Time frame:
On the day of oocyte retrieval (up to 22 days after start of stimulation)
Reported as:
Number · percentage of participants
Proportion of Participants With Extreme Ovarian Responses (Defined as <4, ≥15 or ≥20 Oocytes Retrieved) in Risk Population
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
AMH < 15 pmol/L (<4 oocytes retrieved)11.612.3
AMH >= 15 pmol/L (>=15 oocytes retrieved)22.042.0
AMH >= 15 pmol/L (>=20 oocytes retrieved)8.019.0
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Chi-squared · p = 0.893 (P-value was based on likelihood ratio chi-square test.)
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Chi-squared · p = 0.002 (P-value was based on likelihood ratio chi-square test.)
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Chi-squared · p = 0.021 (P-value based on likelihood ratio chi-square test.)
SecondaryProportion of Participants With Preventive Interventions for Early Ovarian Hyperstimulation Syndrome (OHSS)
Time frame:
≤9 days after triggering of final follicular maturation
Reported as:
Number · percentage of participants
Proportion of Participants With Preventive Interventions for Early Ovarian Hyperstimulation Syndrome (OHSS)
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Cycle cancellation01.1
Triggering with GnRH agonist1.21.1
Administration of dopamine agonist0.61.7
SecondaryProportions of Participants With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS

Defined as proportion of participants with early OHSS, early OHSS of moderate or severe grade, preventive interventions for early OHSS, early OHSS and/or preventive interventions for early OHSS, and early OHSS of moderate or severe grade and/or preventive interventions for early OHSS are presented.

Time frame:
Up to 9 days after triggering of final follicular maturation
Reported as:
Number · percentage of participants
Proportions of Participants With Early OHSS (Including OHSS of Moderate/Severe Grade) and/or Preventive Interventions for Early OHSS
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Early OHSS (any grade)10.018.6
Early OHSS (moderate/severe)6.513.0
Early OHSS (any grade) and/or preventive10.620.9
Early OHSS (moderate/severe) and/or preventive7.616.4
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.017 (P-value was based on likelihood ratio chi-square test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.035 (P-value was based on likelihood ratio chi-square test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.006 (P-value was based on likelihood ratio chi-square test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.009 (P-value was based on likelihood ratio chi-square test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
SecondaryProportions of Participants With Late OHSS (Including OHSS of Moderate/Severe Grade)

Defined as proportions of participants with late OHSS (including OHSS of moderate/severe grade). Late OHSS was defined as OHSS with onset \>9 days after triggering of final follicular maturation. The proportion of participants with late OHSS, and late OHSS of moderate or severe grade are presented. All OHSS cases were graded as mild, moderate, or severe.

Time frame:
>9 days after triggering of final follicular maturation
Reported as:
Number · percentage of participants
Proportions of Participants With Late OHSS (Including OHSS of Moderate/Severe Grade)
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Late OHSS (any grade)1.21.1
Late OHSS (moderate/severe)0.61.1
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.968 (P-value was based on likelihood ratio chi-square test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · Regression, Logistic · p = 0.582 (P-value was based on likelihood ratio chi-square test.)The model included treatment and AMH stratum (\<15 pmol/L and ≥15 pmol/L) as fixed factors.
SecondaryNumber of Follicles on Stimulation Day 6

Defined as the number of follicles observed in both ovaries at the last transvaginal ultrasound (TVUS) in the stimulation phase (on stimulation Day 6).

Time frame:
At Day 6 of stimulation
Reported as:
Mean · Follicles
Number of Follicles on Stimulation Day 6
FolliclesFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Number of Follicles on Stimulation Day 612.8 ± 7.213.3 ± 7.1
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = 0.198 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
SecondaryNumber of Follicles at End-of-stimulation

Defined as the number of follicles observed in both ovaries at the last TVUS in the stimulation phase (end-of-stimulation).

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Mean · Follicles
Number of Follicles at End-of-stimulation
FolliclesFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Number of Follicles at End-of-stimulation14.9 ± 8.016.3 ± 8.8
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = 0.036 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
SecondarySize of Follicles on Stimulation Day 6

Defined as size characteristics of follicles on stimulation Day 6. Average size of 3 largest follicles has been presented in this endpoint.

Time frame:
At Day 6 of stimulation
Reported as:
Mean · mm
Size of Follicles on Stimulation Day 6
mmFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Size of Follicles on Stimulation Day 612.7 ± 2.112.8 ± 2.0
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = 0.592 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
SecondarySize of Follicles at End-of-Stimulation

Defined as size characteristics of follicles at end-of-stimulation. Average size of 3 largest follicles has been presented in this endpoint.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Mean · mm
Size of Follicles at End-of-Stimulation
mmFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Size of Follicles at End-of-Stimulation19.2 ± 1.519.4 ± 1.6
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = 0.286 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
SecondaryFertilization Rate

The fertilization rate was defined as the number of oocytes with 2 pronuclei divided by the number of oocytes retrieved.

Time frame:
Day 1 after oocyte retrieval (up to approximately 22 days after start of stimulation)
Reported as:
Mean · percentage of fertilized oocytes
Fertilization Rate
percentage of fertilized oocytesFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Fertilization Rate54.5 ± 26.157.1 ± 23.4
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = 0.395 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
SecondaryNumber and Quality of Embryos

Number of embryos (total and good-quality) on Day 3 are presented. A good-quality embryo was defined as an embryo with ≥6 blastomeres and fragmentation ≤20% on Day 3.

Time frame:
Day 3 after oocyte retrieval (up to approximately 24 days after start of stimulation)
Reported as:
Mean · Embryo
Number and Quality of Embryos
EmbryoFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Number of embryo5.8 ± 4.27.0 ± 4.3
Number of good-quality embryo3.9 ± 3.34.6 ± 3.3
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = 0.001 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = 0.004 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
SecondaryNumber and Quality of Blastocysts

Number of embryos (total and good-quality) on Day 5 are presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.

Time frame:
Day 5 after oocyte retrieval (up to approximately 26 days after start of stimulation)
Reported as:
Mean · Blastocysts
Number and Quality of Blastocysts
BlastocystsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Number of blastocysts3.1 ± 2.74.2 ± 3.4
Number of good-quality blastocysts2.3 ± 2.33.0 ± 2.6
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = <.001 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = <0.001 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
SecondaryCirculating Levels of Endocrine Parameters (Follicle-stimulating Hormone [FSH], Luteinising Hormone [LH]) on Stimulation Day 6

The median and inter-quartile range (IQR) of FSH and LH levels on stimulation Day 6 are presented.

Time frame:
At Day 6 of stimulation
Reported as:
Median · IU/L
Circulating Levels of Endocrine Parameters (Follicle-stimulating Hormone [FSH], Luteinising Hormone [LH]) on Stimulation Day 6
IU/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
FSH15.4 (12.0 to 19.6)14.7 (12.8 to 17.3)
LH2.6 (1.5 to 6.2)2.8 (1.6 to 5.9)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = 0.228 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 1.03 · 95% CI 0.98 to 1.09Mean ratio is equal to FE 999049/FOLLISTIM.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = 0.777 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 0.97 · 95% CI 0.81 to 1.17Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryCirculating Levels of Endocrine Parameters (Follicle-stimulating Hormone [FSH], Luteinising Hormone [LH]) at End-of-stimulation

The median and IQR of FSH and LH levels at end-of-stimulation are presented.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Median · IU/L
Circulating Levels of Endocrine Parameters (Follicle-stimulating Hormone [FSH], Luteinising Hormone [LH]) at End-of-stimulation
IU/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
FSH14.3 (11.6 to 19.7)16.4 (13.5 to 20.4)
LH1.6 (1.0 to 2.5)1.4 (0.9 to 2.3)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = <0.001 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 0.89 · 95% CI 0.84 to 0.94Mean ratio is equal to FE 999049/FOLLISTIM.
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = 0.057 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 1.17 · 95% CI 1.00 to 1.39Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryCirculating Levels of Endocrine Parameter (Estradiol) on Stimulation Day 6

The median and IQR of estradiol levels on stimulation Day 6 are presented.

Time frame:
At Day 6 of stimulation
Reported as:
Median · pmol/L
Circulating Levels of Endocrine Parameter (Estradiol) on Stimulation Day 6
pmol/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Circulating Levels of Endocrine Parameter (Estradiol) on Stimulation Day 62277.1 (1479.4 to 3580.1)2680.0 (1608.8 to 4685.9)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = 0.002 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 0.81 · 95% CI 0.71 to 0.93Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryCirculating Levels of Endocrine Parameter (Estradiol) at End-of-stimulation

The median and IQR of estradiol levels at end-of-stimulation are presented.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Median · pmol/L
Circulating Levels of Endocrine Parameter (Estradiol) at End-of-stimulation
pmol/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Circulating Levels of Endocrine Parameter (Estradiol) at End-of-stimulation6517.0 (4465.3 to 9033.4)7438.8 (5363.6 to 10283.1)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = 0.003 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 0.85 · 95% CI 0.76 to 0.95Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryCirculating Levels of Endocrine Parameter (Progesterone) on Stimulation Day 6

The median and IQR of progesterone levels on stimulation Day 6 are presented.

Time frame:
At Day 6 of stimulation
Reported as:
Median · nmol/L
Circulating Levels of Endocrine Parameter (Progesterone) on Stimulation Day 6
nmol/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Circulating Levels of Endocrine Parameter (Progesterone) on Stimulation Day 61.7 (0.8 to 2.4)1.7 (0.8 to 2.65)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = 0.814 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 1.02 · 95% CI 0.89 to 1.16Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryCirculating Levels of Endocrine Parameter (Progesterone) at End-of-stimulation

The median and IQR of progesterone levels at end-of-stimulation are presented.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Median · nmol/L
Circulating Levels of Endocrine Parameter (Progesterone) at End-of-stimulation
nmol/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Circulating Levels of Endocrine Parameter (Progesterone) at End-of-stimulation2.5 (1.9 to 3.5)3.1 (2.3 to 4.3)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = <0.001 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 0.78 · 95% CI 0.68 to 0.88Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryCirculating Levels of Endocrine Parameters (Inhibin A) on Stimulation Day 6

The median and IQR of Inhibin A levels on stimulation Day 6 are presented.

Time frame:
At Day 6 of stimulation
Reported as:
Median · ng/L
Circulating Levels of Endocrine Parameters (Inhibin A) on Stimulation Day 6
ng/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Circulating Levels of Endocrine Parameters (Inhibin A) on Stimulation Day 6113.1 (75.1 to 171.9)129.8 (81.6 to 210.6)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = <0.001 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 0.82 · 95% CI 0.73 to 0.92Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryCirculating Levels of Endocrine Parameters (Inhibin A) at End-of-stimulation

The median and IQR of Inhibin A levels at end-of-stimulation are presented.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Median · ng/L
Circulating Levels of Endocrine Parameters (Inhibin A) at End-of-stimulation
ng/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Circulating Levels of Endocrine Parameters (Inhibin A) at End-of-stimulation323.8 (222.1 to 458.8)390.3 (301.0 to 551.1)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = <0.001 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 0.80 · 95% CI 0.72 to 0.88Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryCirculating Levels of Endocrine Parameters (Inhibin B) on Stimulation Day 6

The median and IQR of inhibin B levels on stimulation Day 6 are presented.

Time frame:
At Day 6 of stimulation
Reported as:
Median · ng/L
Circulating Levels of Endocrine Parameters (Inhibin B) on Stimulation Day 6
ng/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Circulating Levels of Endocrine Parameters (Inhibin B) on Stimulation Day 6570.5 (396.0 to 853.0)686.0 (431.0 to 1004.0)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = <0.001 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 0.83 · 95% CI 0.75 to 0.93Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryCirculating Levels of Endocrine Parameters (Inhibin B) at End-of-stimulation

The median and IQR of inhibin B levels at end-of-stimulation are presented.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Median · ng/L
Circulating Levels of Endocrine Parameters (Inhibin B) at End-of-stimulation
ng/LFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Circulating Levels of Endocrine Parameters (Inhibin B) at End-of-stimulation686.0 (461.0 to 1057.0)734.5 (492.5 to 1120.5)
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · ANCOVA · p = 0.027 (The P-value corresponds to the two-sided F-test of treatment effect.) · Mean ratio: 0.88 · 95% CI 0.79 to 0.99Mean ratio is equal to FE 999049/FOLLISTIM.
SecondaryNumber of Stimulation Days
Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Mean · Days
Number of Stimulation Days
DaysFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Number of Stimulation Days8.9 ± 1.98.8 ± 1.7
Statistical analysis
  • FE 999049 (Follitropin Delta) vs FOLLISTIM (Follitropin Beta) · van Elteren test · p = 0.694 (2-sided)P-value was based on van Elteren test adjusted for AMH strata.
SecondaryTotal Gonadotropin Dose of FE 999049
Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Mean · μg
Total Gonadotropin Dose of FE 999049
μgFE 999049 (Follitropin Delta)
Total Gonadotropin Dose of FE 99904983.5 ± 28.9
SecondaryTotal Gonadotropin Dose of FOLLISTIM
Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Mean · IU
Total Gonadotropin Dose of FOLLISTIM
IUFOLLISTIM (Follitropin Beta)
Total Gonadotropin Dose of FOLLISTIM1499 ± 514
SecondaryNumber of Participants With Adverse Events (AEs) Stratified by Intensity

The frequency of participants with total AEs and AEs by categories of intensity (mild, moderate, severe) are presented. An AE was any untoward medical occurrence in a participants participating in clinical trial. The intensity of AE was classified using the following 3-point scale: mild = awareness of signs or symptoms, but no disruption of usual activity); moderate = event sufficient to affect usual activity (disturbing); or severe = inability to work or perform usual activities (unacceptable).

Time frame:
From signed informed consent up to 5-6 weeks after transfer
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs) Stratified by Intensity
ParticipantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Any AE7392
Mild AE6986
Moderate AE812
Severe AE01
SecondaryProportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-stimulation

Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) were reported. The clinical chemistry parameters included: alanine transaminase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · participants
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-stimulation
participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
ALT (IU/L): Normal to markedly high (>3xULN)01
AST (IU/L): Normal to markedly high (>3xULN)01
SecondaryProportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-stimulation

Defined as number of participants with at least one markedly abnormal changes in hematology parameters (as assessed by investigator) were reported. Hematology parameters included: red blood cells, white blood cells, red blood cells morphology, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · participants
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-stimulation
participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-stimulation00
SecondaryProportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-trial

Defined as number of participants with at least one markedly abnormal finding in clinical chemistry parameters (as assessed by investigator) were reported. The clinical chemistry parameters included: alanine transaminase (ALT), albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), bicarbonate, bilirubin direct, bilirubin total, blood urea nitrogen, calcium, chloride, cholesterol total, creatinine, gamma-glutamyl transpeptidase, glucose, lactate dehydrogenase, phosphorus, potassium, sodium, total protein, uric acid.

Time frame:
Up to 5-6 weeks after transfer
Reported as:
Number · participants
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-trial
participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Clinical Chemistry Parameters at End-of-trial00
SecondaryProportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-trial

Defined as number of participants with at least one markedly abnormal changes in hematology parameters (as assessed by investigator) were reported. Hematology parameters included: red blood cells, white blood cells, red blood cells morphology, white blood cells morphology, haemoglobin, haematocrit, mean corpuscular volume, mean corpuscular haemoglobin, mean corpuscular haemoglobin concentration, platelets.

Time frame:
Up to 5-6 weeks after transfer
Reported as:
Number · participants
Proportion of Participants Who Had Markedly Abnormal Value Changes From Baseline in Hematology Parameters at End-of-trial
participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Leukocytes (10^9/L) Normal to markedly high (>=16)01
Hemoglobin (g/L) Normal to markedly low01
Hematocrit (ratio) Normal to markedly low (>=0.56)01
SecondaryFrequency and Intensity of Injection Site Reactions

The presence of of injection site reactions (redness, itching, pain, swelling and bruising) immediately, 30 minutes and 24 hours after the injection are presented. The injection site reactions were assessed as none, mild, moderate and severe. The number of injection site reactions (mild, moderate or severe) based on all assessments performed is presented.

Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · events
Frequency and Intensity of Injection Site Reactions
eventsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Any mild injection site reaction271719
Any moderate injection site reaction719
Any severe injection site reaction10
Mild redness140174
Moderate redness20
Severe redness00
Mild itching45
Moderate itching10
Severe itching00
Mild pain19411
Moderate pain116
Severe pain00
Mild swelling610
Moderate swelling00
Severe swelling00
Mild bruising102119
Moderate bruising33
Severe bruising10
SecondaryTechnical Malfunctions of the Administration Pens
Time frame:
End-of-stimulation (up to 20 stimulation days)
Reported as:
Number · percentage of participants
Technical Malfunctions of the Administration Pens
percentage of participantsFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Technical Malfunctions of the Administration Pens00

Adverse events

Collected over Adverse events were monitored from the time of obtaining informed consent until the last visit (end-of-trial) (up to approximately 2 years) .. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FE 999049 (Follitropin Delta)0/170 (0%)0/170 (0%)73/170 (42.9%)
FOLLISTIM (Follitropin Beta)0/177 (0%)2/177 (1.1%)92/177 (52%)
Most frequent serious events
Most frequent serious events
EventFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Ovarian hyperstimulation syndromeReproductive system and breast disorders0/1702/177
Most frequent other events
Showing 10 of 12
Most frequent other events
EventFE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)
Ovarian hyperstimulation syndromeReproductive system and breast disorders19/17035/177
Injection site erythemaGeneral disorders13/17015/177
Biochemical pregnancyPregnancy, puerperium and perinatal conditions6/17010/177
Ovarian cystReproductive system and breast disorders5/1707/177
Viral upper respiratory tract infectionInfections and infestations6/1706/177
Ovarian enlargementReproductive system and breast disorders5/1705/177
ConstipationGastrointestinal disorders4/1705/177
Injection site pruritusGeneral disorders0/1705/177
HeadacheNervous system disorders4/1704/177
Haemorrhage in pregnancyPregnancy, puerperium and perinatal conditions4/1700/177

Baseline characteristics

Age, Continuous
Age, Continuous(years)FE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)Total
Mean34.2 ± 3.534.0 ± 3.434.1 ± 3.5
Sex: Female, Male
Sex: Female, Male(Participants)FE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)Total
Female170177347
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)Total
Hispanic or Latino000
Not Hispanic or Latino170177347
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)Total
American Indian or Alaska Native000
Asian170177347
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)FE 999049 (Follitropin Delta)FOLLISTIM (Follitropin Beta)Total
Japan170177347
08

Study locations

17 sites
  • Yachiyo Hospital
    Anjo, Aichi, Japan
  • Investigational Site 8121
    Chiba-shi, Chiba, Japan
  • Yokota Maternity Hospital
    Maebashi, Gunma, Japan
  • Sophia Ladies Clinic
    Sagamihara, Kanagawa, Japan
  • Investigational Site 8122
    Sendai-shi, Miyagi, Japan
  • Investigational Site 8123
    Higashiōsaka-shi, Osaka, Japan
  • Investigational Site 8120
    Osaka-Shi, Osaka, Japan
  • Ladies Clinic Kitahama
    Osaka-shi, Osaka, Japan
  • Investigational Site 8125
    Saitama-shi, Saitama, Japan
  • Investigational Site 8124
    Shinjuku-Ku, Tokyo, Japan
  • Akita University Hospital
    Akita, Japan
  • Yamashita Ladies' Clinic
    Hyogo, Japan
  • Investigational Site 8126
    Saitama, Japan
  • Omiya Ladies Clinic
    Saitama, Japan
  • Saint Women's Clinic
    Saitama, Japan
  • Women's Clinic Fujimino
    Saitama, Japan
  • Tokushima University Hospital
    Tokushima, Japan
09

References and documents

Publications

  • Ishihara O, Arce JC; Japanese Follitropin Delta Phase 3 Trial (STORK) Group. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021 May;42(5):909-918. doi: 10.1016/j.rbmo.2021.01.023. Epub 2021 Feb 9. PubMed 33722477 ↗
  • Ishihara O, Nelson SM, Arce JC. Comparison of ovarian response to follitropin delta in Japanese and White IVF/ICSI patients. Reprod Biomed Online. 2022 Jan;44(1):177-184. doi: 10.1016/j.rbmo.2021.09.014. Epub 2021 Sep 23. PubMed 34799275 ↗
  • Fernandez-Sanchez M, Fatemi H, Garcia-Velasco JA, Heiser PW, Daftary GS, Mannaerts B. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach. Gynecol Endocrinol. 2023 Dec;39(1):2205952. doi: 10.1080/09513590.2023.2205952. PubMed 37156263 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jun 2019, 22 months.

Results were first posted in Mar 2021, 1 year 9 months after primary completion.

Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 22 months is above that.

Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2017
First posted
Jul 25, 2017
StartActual
Jul 29, 2017
Primary completionActual
Jun 10, 2019
CompletionActual
Jul 8, 2019
Results first posted
Mar 24, 2021
Last update
Aug 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03228680
Responsible party
Sponsor
First posted
Jul 25, 2017
Start date
Jul 29, 2017
Primary completion
Jun 10, 2019
Completion
Jul 8, 2019
Results posted
Mar 24, 2021
Last update
Aug 24, 2023

Study contacts

Global Clinical Compliance
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion